Loading trials...
Searching ClinicalTrials.gov...
We surface recruiting trials for AML, CML, ALL, and CLL from ClinicalTrials.gov. Your specific mutation — FLT3, IDH1/2, NPM1, BCR-ABL, or CD19 — determines which trials you qualify for and which to prioritize.
Searching ClinicalTrials.gov...
Leukemia trial eligibility is driven by your specific mutation profile. These are the most actionable biomarkers across AML, CML, ALL, and CLL — find them on your bone marrow biopsy or molecular panel report.
FLT3-ITD is found in ~30% of AML patients and is one of the most actionable mutations. Approved agents: midostaurin (Rydapt) and gilteritinib (Xospata). Active trials include quizartinib combinations, next-generation FLT3 inhibitors in frontline settings, and post-transplant maintenance trials.
Confirm your FLT3 subtype (ITD vs TKD) — both qualify for trials but with different response profiles.
Imatinib resistance is usually caused by BCR-ABL kinase domain mutations. The first step is testing for T315I mutation — it resists most TKIs but responds to ponatinib (Iclusig) and asciminib (Scemblix). Trials are available for ponatinib combinations, novel allosteric inhibitors, and CML in blast crisis.
CAR-T therapy engineers your own T-cells to attack cancer. For ALL, CD19-targeted CAR-T (tisagenlecleucel, brexucabtagene) is approved for relapsed/refractory disease. Trials are expanding to first-line, CD22 targets, and dual-target constructs.
Key eligibility factors: CD19 expression level, number of prior treatment lines, performance status, and organ function. CLL patients may also qualify at academic centers.
IDH mutations affect ~20% of AML patients. Approved: enasidenib for IDH2, ivosidenib for IDH1. Active trials include IDH inhibitor + venetoclax + azacitidine combinations, frontline settings, and novel agents like olutasidenib.
IDH mutation testing should be part of your initial AML workup — ask your hematologist if it was performed.
Yes. Post-transplant relapse trial options include: donor lymphocyte infusion (DLI) combinations, second CAR-T infusions, bispecific antibody trials (flotetuzumab, CD3xCD123), and novel targeted agents. The speed of relapse relative to transplant date matters for eligibility.
Several academic centers have specific post-transplant relapse protocols. Upload your transplant records to match accurately.
Leukemia trials often enroll faster than solid tumor trials. The fastest path: (1) Ask your hematologist if your center participates in NCI cooperative group trials (ECOG-ACRIN, SWOG, Alliance). (2) Contact the coordinator the same day with your mutation profile and treatment history. (3) Pre-screening calls can often happen within 24–48 hours.
Phase 1 tests safety. Phase 2 tests whether the treatment works. Phase 3 compares the new treatment against the current standard. Most patients look for Phase 2 or 3 trials, where the treatment has shown early promise.
Every trial has a checklist of who can and cannot join. These might include your cancer stage, specific gene mutations, prior treatments, age, and overall health. Meeting these is required — not optional.
No. The experimental treatment in a clinical trial is free. You may still have to pay for routine care like doctor visits, but the trial drug or procedure itself is covered by the sponsor.
Recruiting means the trial is actively looking for participants right now. "Not yet recruiting" means it's approved but hasn't started. "Active, not recruiting" means it's ongoing but has all the participants it needs.